APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global First in Class (FIC) Antibody Drugs Market Outlook and Growth Opportunities 2026

Report ID 173992050423 December 2025215 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drugs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drugs Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the First in Class (FIC) Antibody Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the First in Class (FIC) Antibody Drugs market include Suzhou Zejing Biopharmaceutical, Foreseen Biotechnology, Shenzhen Yipusheng, Suzhou Yilian Biopharmaceutical, Beijing Hotgen Biotech, Johnson & Johnson, Lixin Pharmaceutical Technology, Akeso, Inc and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global First in Class (FIC) Antibody Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of First in Class (FIC) Antibody Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents First in Class (FIC) Antibody Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the First in Class (FIC) Antibody Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

First in Class (FIC) Antibody Drugs Segment by Company

Suzhou Zejing Biopharmaceutical

Foreseen Biotechnology

Shenzhen Yipusheng

Suzhou Yilian Biopharmaceutical

Beijing Hotgen Biotech

Johnson & Johnson

Lixin Pharmaceutical Technology

Akeso, Inc

Pfizer

Jiangsu Hengrui Medicine

GSK

Shanghai Henlius Biotech, Inc.

Dizal Pharma

AstraZeneca

Vertex Pharmaceuticals

Truqap

Telix

Talvey

Skyclary

Regeneron Pharmaceuticals

Pumis Biotechnology (BioNTech)

Ogsiveo

Merus

Lytgobi

Litfulo

Immatics

Fabhalta

Bicara Therapeutics

Bayer Corporation

Arvinas

First in Class (FIC) Antibody Drugs Segment by Type

Large Molecule FIC Drugs

Small Molecule FIC Drugs

First in Class (FIC) Antibody Drugs Segment by Application

Tumors and Cancers

Nervous System Diseases

Others

First in Class (FIC) Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global First in Class (FIC) Antibody Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions First in Class (FIC) Antibody Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify First in Class (FIC) Antibody Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze First in Class (FIC) Antibody Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the First in Class (FIC) Antibody Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global First in Class (FIC) Antibody Drugs industry.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of First in Class (FIC) Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of First in Class (FIC) Antibody Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. First in Class (FIC) Antibody Drugs Industry Trends Table 2. First in Class (FIC) Antibody Drugs Industry Drivers Table 3. First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges Table 4. First in Class (FIC) Antibody Drugs Industry Restraints Table 5. Global First in Class (FIC) Antibody Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global First in Class (FIC) Antibody Drugs Revenue Share by Company (2021-2026) Table 7. Global First in Class (FIC) Antibody Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global First in Class (FIC) Antibody Drugs Sales Volume Share by Company (2021-2026) Table 9. Global First in Class (FIC) Antibody Drugs Average Price (USD/unit) of Company (2021-2026) Table 10. Global First in Class (FIC) Antibody Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global First in Class (FIC) Antibody Drugs Key Company Manufacturing Base & Headquarters Table 12. Global First in Class (FIC) Antibody Drugs Company, Product Type & Application Table 13. Global First in Class (FIC) Antibody Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global First in Class (FIC) Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Large Molecule FIC Drugs Table 18. Significant Companies of Small Molecule FIC Drugs Table 19. Global First in Class (FIC) Antibody Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global First in Class (FIC) Antibody Drugs Sales Volume by Type (2021-2026) & (k units) Table 21. Global First in Class (FIC) Antibody Drugs Sales Volume by Type (2027-2032) & (k units) Table 22. Global First in Class (FIC) Antibody Drugs Sales Volume Share by Type (2021-2026) Table 23. Global First in Class (FIC) Antibody Drugs Sales Volume Share by Type (2027-2032) Table 24. Global First in Class (FIC) Antibody Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global First in Class (FIC) Antibody Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global First in Class (FIC) Antibody Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global First in Class (FIC) Antibody Drugs Sales Value Share by Type (2021-2026) Table 28. Global First in Class (FIC) Antibody Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Tumors and Cancers Table 30. Significant Companies of Nervous System Diseases Table 31. Significant Companies of Others Table 32. Global First in Class (FIC) Antibody Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global First in Class (FIC) Antibody Drugs Sales Volume by Application (2021-2026) & (k units) Table 34. Global First in Class (FIC) Antibody Drugs Sales Volume by Application (2027-2032) & (k units) Table 35. Global First in Class (FIC) Antibody Drugs Sales Volume Share by Application (2021-2026) Table 36. Global First in Class (FIC) Antibody Drugs Sales Volume Share by Application (2027-2032) Table 37. Global First in Class (FIC) Antibody Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global First in Class (FIC) Antibody Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global First in Class (FIC) Antibody Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global First in Class (FIC) Antibody Drugs Sales Value Share by Application (2021-2026) Table 41. Global First in Class (FIC) Antibody Drugs Sales Value Share by Application (2027-2032) Table 42. Global First in Class (FIC) Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026) & (k units) Table 44. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2021-2026) Table 45. Global First in Class (FIC) Antibody Drugs Sales by Region (2027-2032) & (k units) Table 46. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2027-2032) Table 47. Global First in Class (FIC) Antibody Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global First in Class (FIC) Antibody Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global First in Class (FIC) Antibody Drugs Sales Value Share by Region (2021-2026) Table 50. Global First in Class (FIC) Antibody Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global First in Class (FIC) Antibody Drugs Sales Value Share by Region (2027-2032) Table 52. Global First in Class (FIC) Antibody Drugs Market Average Price (USD/unit) by Region (2021-2026) Table 53. Global First in Class (FIC) Antibody Drugs Market Average Price (USD/unit) by Region (2027-2032) Table 54. Global First in Class (FIC) Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global First in Class (FIC) Antibody Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 57. Global First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2026) Table 58. Global First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 59. Global First in Class (FIC) Antibody Drugs Sales Market Share by Country (2027-2032) Table 60. Global First in Class (FIC) Antibody Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global First in Class (FIC) Antibody Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global First in Class (FIC) Antibody Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global First in Class (FIC) Antibody Drugs Sales Value Market Share by Country (2027-2032) Table 64. Suzhou Zejing Biopharmaceutical Company Information Table 65. Suzhou Zejing Biopharmaceutical Business Overview Table 66. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 67. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 68. Suzhou Zejing Biopharmaceutical Recent Development Table 69. Foreseen Biotechnology Company Information Table 70. Foreseen Biotechnology Business Overview Table 71. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 72. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio Table 73. Foreseen Biotechnology Recent Development Table 74. Shenzhen Yipusheng Company Information Table 75. Shenzhen Yipusheng Business Overview Table 76. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio Table 78. Shenzhen Yipusheng Recent Development Table 79. Suzhou Yilian Biopharmaceutical Company Information Table 80. Suzhou Yilian Biopharmaceutical Business Overview Table 81. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 82. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 83. Suzhou Yilian Biopharmaceutical Recent Development Table 84. Beijing Hotgen Biotech Company Information Table 85. Beijing Hotgen Biotech Business Overview Table 86. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio Table 88. Beijing Hotgen Biotech Recent Development Table 89. Johnson & Johnson Company Information Table 90. Johnson & Johnson Business Overview Table 91. Johnson & Johnson First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio Table 93. Johnson & Johnson Recent Development Table 94. Lixin Pharmaceutical Technology Company Information Table 95. Lixin Pharmaceutical Technology Business Overview Table 96. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio Table 98. Lixin Pharmaceutical Technology Recent Development Table 99. Akeso, Inc Company Information Table 100. Akeso, Inc Business Overview Table 101. Akeso, Inc First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio Table 103. Akeso, Inc Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Pfizer First in Class (FIC) Antibody Drugs Product Portfolio Table 108. Pfizer Recent Development Table 109. Jiangsu Hengrui Medicine Company Information Table 110. Jiangsu Hengrui Medicine Business Overview Table 111. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio Table 113. Jiangsu Hengrui Medicine Recent Development Table 114. GSK Company Information Table 115. GSK Business Overview Table 116. GSK First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. GSK First in Class (FIC) Antibody Drugs Product Portfolio Table 118. GSK Recent Development Table 119. Shanghai Henlius Biotech, Inc. Company Information Table 120. Shanghai Henlius Biotech, Inc. Business Overview Table 121. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio Table 123. Shanghai Henlius Biotech, Inc. Recent Development Table 124. Dizal Pharma Company Information Table 125. Dizal Pharma Business Overview Table 126. Dizal Pharma First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio Table 128. Dizal Pharma Recent Development Table 129. AstraZeneca Company Information Table 130. AstraZeneca Business Overview Table 131. AstraZeneca First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio Table 133. AstraZeneca Recent Development Table 134. Vertex Pharmaceuticals Company Information Table 135. Vertex Pharmaceuticals Business Overview Table 136. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 138. Vertex Pharmaceuticals Recent Development Table 139. Truqap Company Information Table 140. Truqap Business Overview Table 141. Truqap First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 142. Truqap First in Class (FIC) Antibody Drugs Product Portfolio Table 143. Truqap Recent Development Table 144. Telix Company Information Table 145. Telix Business Overview Table 146. Telix First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 147. Telix First in Class (FIC) Antibody Drugs Product Portfolio Table 148. Telix Recent Development Table 149. Talvey Company Information Table 150. Talvey Business Overview Table 151. Talvey First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 152. Talvey First in Class (FIC) Antibody Drugs Product Portfolio Table 153. Talvey Recent Development Table 154. Skyclary Company Information Table 155. Skyclary Business Overview Table 156. Skyclary First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 157. Skyclary First in Class (FIC) Antibody Drugs Product Portfolio Table 158. Skyclary Recent Development Table 159. Regeneron Pharmaceuticals Company Information Table 160. Regeneron Pharmaceuticals Business Overview Table 161. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 162. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 163. Regeneron Pharmaceuticals Recent Development Table 164. Pumis Biotechnology (BioNTech) Company Information Table 165. Pumis Biotechnology (BioNTech) Business Overview Table 166. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 167. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio Table 168. Pumis Biotechnology (BioNTech) Recent Development Table 169. Ogsiveo Company Information Table 170. Ogsiveo Business Overview Table 171. Ogsiveo First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 172. Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio Table 173. Ogsiveo Recent Development Table 174. Merus Company Information Table 175. Merus Business Overview Table 176. Merus First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 177. Merus First in Class (FIC) Antibody Drugs Product Portfolio Table 178. Merus Recent Development Table 179. Lytgobi Company Information Table 180. Lytgobi Business Overview Table 181. Lytgobi First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 182. Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio Table 183. Lytgobi Recent Development Table 184. Litfulo Company Information Table 185. Litfulo Business Overview Table 186. Litfulo First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 187. Litfulo First in Class (FIC) Antibody Drugs Product Portfolio Table 188. Litfulo Recent Development Table 189. Immatics Company Information Table 190. Immatics Business Overview Table 191. Immatics First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 192. Immatics First in Class (FIC) Antibody Drugs Product Portfolio Table 193. Immatics Recent Development Table 194. Fabhalta Company Information Table 195. Fabhalta Business Overview Table 196. Fabhalta First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 197. Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio Table 198. Fabhalta Recent Development Table 199. Bicara Therapeutics Company Information Table 200. Bicara Therapeutics Business Overview Table 201. Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 202. Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio Table 203. Bicara Therapeutics Recent Development Table 204. Bayer Corporation Company Information Table 205. Bayer Corporation Business Overview Table 206. Bayer Corporation First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 207. Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio Table 208. Bayer Corporation Recent Development Table 209. Arvinas Company Information Table 210. Arvinas Business Overview Table 211. Arvinas First in Class (FIC) Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 212. Arvinas First in Class (FIC) Antibody Drugs Product Portfolio Table 213. Arvinas Recent Development Table 214. Key Raw Materials Table 215. Raw Materials Key Suppliers Table 216. First in Class (FIC) Antibody Drugs Distributors List Table 217. First in Class (FIC) Antibody Drugs Customers List Table 218. Research Programs/Design for This Report Table 219. Authors List of This Report Table 220. Secondary Sources Table 221. Primary Sources List of Figures Figure 1. First in Class (FIC) Antibody Drugs Product Image Figure 2. Global First in Class (FIC) Antibody Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global First in Class (FIC) Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global First in Class (FIC) Antibody Drugs Sales (2021-2032) & (k units) Figure 5. Global First in Class (FIC) Antibody Drugs Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global First in Class (FIC) Antibody Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Large Molecule FIC Drugs Image Figure 10. Small Molecule FIC Drugs Image Figure 11. Global First in Class (FIC) Antibody Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global First in Class (FIC) Antibody Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global First in Class (FIC) Antibody Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global First in Class (FIC) Antibody Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global First in Class (FIC) Antibody Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global First in Class (FIC) Antibody Drugs Sales Value Share by Type (2021-2032) Figure 17. Tumors and Cancers Image Figure 18. Nervous System Diseases Image Figure 19. Others Image Figure 20. Global First in Class (FIC) Antibody Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global First in Class (FIC) Antibody Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global First in Class (FIC) Antibody Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global First in Class (FIC) Antibody Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global First in Class (FIC) Antibody Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global First in Class (FIC) Antibody Drugs Sales Value Share by Application (2021-2032) Figure 26. Global First in Class (FIC) Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global First in Class (FIC) Antibody Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global First in Class (FIC) Antibody Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America First in Class (FIC) Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America First in Class (FIC) Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe First in Class (FIC) Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe First in Class (FIC) Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific First in Class (FIC) Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America First in Class (FIC) Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America First in Class (FIC) Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa First in Class (FIC) Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa First in Class (FIC) Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. First in Class (FIC) Antibody Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. First in Class (FIC) Antibody Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Large Molecule FIC Drugs
  • Small Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Nervous System Diseases
  • Others
Companies covered
  • Suzhou Zejing Biopharmaceutical
  • Foreseen Biotechnology
  • Shenzhen Yipusheng
  • Suzhou Yilian Biopharmaceutical
  • Beijing Hotgen Biotech
  • Johnson & Johnson
  • Lixin Pharmaceutical Technology
  • Akeso, Inc
  • Pfizer
  • Jiangsu Hengrui Medicine
  • GSK
  • Shanghai Henlius Biotech, Inc.
  • Dizal Pharma
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Truqap
  • Telix
  • Talvey
  • Skyclary
  • Regeneron Pharmaceuticals
  • Pumis Biotechnology (BioNTech)
  • Ogsiveo
  • Merus
  • Lytgobi
  • Litfulo
  • Immatics
  • Fabhalta
  • Bicara Therapeutics
  • Bayer Corporation
  • Arvinas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global First in Class (FIC) Antibody Drugs Sales Value (2021-2032)
  4. 1.2.2 Global First in Class (FIC) Antibody Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global First in Class (FIC) Antibody Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 First in Class (FIC) Antibody Drugs Market Dynamics
  1. 2.1 First in Class (FIC) Antibody Drugs Industry Trends
  2. 2.2 First in Class (FIC) Antibody Drugs Industry Drivers
  3. 2.3 First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges
  4. 2.4 First in Class (FIC) Antibody Drugs Industry Restraints
3 First in Class (FIC) Antibody Drugs Market by Company
  1. 3.1 Global First in Class (FIC) Antibody Drugs Company Revenue Ranking in 2025
  2. 3.2 Global First in Class (FIC) Antibody Drugs Revenue by Company (2021-2026)
  3. 3.3 Global First in Class (FIC) Antibody Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drugs Average Price by Company (2021-2026)
  5. 3.5 Global First in Class (FIC) Antibody Drugs Company Ranking (2024-2026)
  6. 3.6 Global First in Class (FIC) Antibody Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global First in Class (FIC) Antibody Drugs Company Product Type and Application
  8. 3.8 Global First in Class (FIC) Antibody Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global First in Class (FIC) Antibody Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 First in Class (FIC) Antibody Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 First in Class (FIC) Antibody Drugs Market by Type
  1. 4.1 First in Class (FIC) Antibody Drugs Type Introduction
  2. 4.1.1 Large Molecule FIC Drugs
  3. 4.1.2 Small Molecule FIC Drugs
  4. 4.2 Global First in Class (FIC) Antibody Drugs Sales Volume by Type
  5. 4.2.1 Global First in Class (FIC) Antibody Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global First in Class (FIC) Antibody Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global First in Class (FIC) Antibody Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global First in Class (FIC) Antibody Drugs Sales Value by Type
  9. 4.3.1 Global First in Class (FIC) Antibody Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global First in Class (FIC) Antibody Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global First in Class (FIC) Antibody Drugs Sales Value Share by Type (2021-2032)
5 First in Class (FIC) Antibody Drugs Market by Application
  1. 5.1 First in Class (FIC) Antibody Drugs Application Introduction
  2. 5.1.1 Tumors and Cancers
  3. 5.1.2 Nervous System Diseases
  4. 5.1.3 Others
  5. 5.2 Global First in Class (FIC) Antibody Drugs Sales Volume by Application
  6. 5.2.1 Global First in Class (FIC) Antibody Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global First in Class (FIC) Antibody Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global First in Class (FIC) Antibody Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global First in Class (FIC) Antibody Drugs Sales Value by Application
  10. 5.3.1 Global First in Class (FIC) Antibody Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global First in Class (FIC) Antibody Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global First in Class (FIC) Antibody Drugs Sales Value Share by Application (2021-2032)
6 First in Class (FIC) Antibody Drugs Regional Sales and Value Analysis
  1. 6.1 Global First in Class (FIC) Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global First in Class (FIC) Antibody Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global First in Class (FIC) Antibody Drugs Sales by Region (2027-2032)
  5. 6.3 Global First in Class (FIC) Antibody Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global First in Class (FIC) Antibody Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global First in Class (FIC) Antibody Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global First in Class (FIC) Antibody Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global First in Class (FIC) Antibody Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America First in Class (FIC) Antibody Drugs Sales Value (2021-2032)
  12. 6.6.2 North America First in Class (FIC) Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe First in Class (FIC) Antibody Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe First in Class (FIC) Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific First in Class (FIC) Antibody Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific First in Class (FIC) Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America First in Class (FIC) Antibody Drugs Sales Value (2021-2032)
  21. 6.9.2 South America First in Class (FIC) Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa First in Class (FIC) Antibody Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa First in Class (FIC) Antibody Drugs Sales Value Share by Country, 2025 VS 2032
7 First in Class (FIC) Antibody Drugs Country-level Sales and Value Analysis
  1. 7.1 Global First in Class (FIC) Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global First in Class (FIC) Antibody Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global First in Class (FIC) Antibody Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global First in Class (FIC) Antibody Drugs Sales by Country (2027-2032)
  6. 7.4 Global First in Class (FIC) Antibody Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global First in Class (FIC) Antibody Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global First in Class (FIC) Antibody Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt First in Class (FIC) Antibody Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt First in Class (FIC) Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt First in Class (FIC) Antibody Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Suzhou Zejing Biopharmaceutical
  2. 8.1.1 Suzhou Zejing Biopharmaceutical Company Information
  3. 8.1.2 Suzhou Zejing Biopharmaceutical Business Overview
  4. 8.1.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  6. 8.1.5 Suzhou Zejing Biopharmaceutical Recent Developments
  7. 8.2 Foreseen Biotechnology
  8. 8.2.1 Foreseen Biotechnology Company Information
  9. 8.2.2 Foreseen Biotechnology Business Overview
  10. 8.2.3 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio
  12. 8.2.5 Foreseen Biotechnology Recent Developments
  13. 8.3 Shenzhen Yipusheng
  14. 8.3.1 Shenzhen Yipusheng Company Information
  15. 8.3.2 Shenzhen Yipusheng Business Overview
  16. 8.3.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio
  18. 8.3.5 Shenzhen Yipusheng Recent Developments
  19. 8.4 Suzhou Yilian Biopharmaceutical
  20. 8.4.1 Suzhou Yilian Biopharmaceutical Company Information
  21. 8.4.2 Suzhou Yilian Biopharmaceutical Business Overview
  22. 8.4.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  24. 8.4.5 Suzhou Yilian Biopharmaceutical Recent Developments
  25. 8.5 Beijing Hotgen Biotech
  26. 8.5.1 Beijing Hotgen Biotech Company Information
  27. 8.5.2 Beijing Hotgen Biotech Business Overview
  28. 8.5.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio
  30. 8.5.5 Beijing Hotgen Biotech Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Lixin Pharmaceutical Technology
  38. 8.7.1 Lixin Pharmaceutical Technology Company Information
  39. 8.7.2 Lixin Pharmaceutical Technology Business Overview
  40. 8.7.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio
  42. 8.7.5 Lixin Pharmaceutical Technology Recent Developments
  43. 8.8 Akeso, Inc
  44. 8.8.1 Akeso, Inc Company Information
  45. 8.8.2 Akeso, Inc Business Overview
  46. 8.8.3 Akeso, Inc First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio
  48. 8.8.5 Akeso, Inc Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer First in Class (FIC) Antibody Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Jiangsu Hengrui Medicine
  56. 8.10.1 Jiangsu Hengrui Medicine Company Information
  57. 8.10.2 Jiangsu Hengrui Medicine Business Overview
  58. 8.10.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio
  60. 8.10.5 Jiangsu Hengrui Medicine Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GSK First in Class (FIC) Antibody Drugs Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Shanghai Henlius Biotech, Inc.
  68. 8.12.1 Shanghai Henlius Biotech, Inc. Company Information
  69. 8.12.2 Shanghai Henlius Biotech, Inc. Business Overview
  70. 8.12.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio
  72. 8.12.5 Shanghai Henlius Biotech, Inc. Recent Developments
  73. 8.13 Dizal Pharma
  74. 8.13.1 Dizal Pharma Company Information
  75. 8.13.2 Dizal Pharma Business Overview
  76. 8.13.3 Dizal Pharma First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio
  78. 8.13.5 Dizal Pharma Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Vertex Pharmaceuticals
  86. 8.15.1 Vertex Pharmaceuticals Company Information
  87. 8.15.2 Vertex Pharmaceuticals Business Overview
  88. 8.15.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  90. 8.15.5 Vertex Pharmaceuticals Recent Developments
  91. 8.16 Truqap
  92. 8.16.1 Truqap Company Information
  93. 8.16.2 Truqap Business Overview
  94. 8.16.3 Truqap First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Truqap First in Class (FIC) Antibody Drugs Product Portfolio
  96. 8.16.5 Truqap Recent Developments
  97. 8.17 Telix
  98. 8.17.1 Telix Company Information
  99. 8.17.2 Telix Business Overview
  100. 8.17.3 Telix First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Telix First in Class (FIC) Antibody Drugs Product Portfolio
  102. 8.17.5 Telix Recent Developments
  103. 8.18 Talvey
  104. 8.18.1 Talvey Company Information
  105. 8.18.2 Talvey Business Overview
  106. 8.18.3 Talvey First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Talvey First in Class (FIC) Antibody Drugs Product Portfolio
  108. 8.18.5 Talvey Recent Developments
  109. 8.19 Skyclary
  110. 8.19.1 Skyclary Company Information
  111. 8.19.2 Skyclary Business Overview
  112. 8.19.3 Skyclary First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Skyclary First in Class (FIC) Antibody Drugs Product Portfolio
  114. 8.19.5 Skyclary Recent Developments
  115. 8.20 Regeneron Pharmaceuticals
  116. 8.20.1 Regeneron Pharmaceuticals Company Information
  117. 8.20.2 Regeneron Pharmaceuticals Business Overview
  118. 8.20.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  120. 8.20.5 Regeneron Pharmaceuticals Recent Developments
  121. 8.21 Pumis Biotechnology (BioNTech)
  122. 8.21.1 Pumis Biotechnology (BioNTech) Company Information
  123. 8.21.2 Pumis Biotechnology (BioNTech) Business Overview
  124. 8.21.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio
  126. 8.21.5 Pumis Biotechnology (BioNTech) Recent Developments
  127. 8.22 Ogsiveo
  128. 8.22.1 Ogsiveo Company Information
  129. 8.22.2 Ogsiveo Business Overview
  130. 8.22.3 Ogsiveo First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio
  132. 8.22.5 Ogsiveo Recent Developments
  133. 8.23 Merus
  134. 8.23.1 Merus Company Information
  135. 8.23.2 Merus Business Overview
  136. 8.23.3 Merus First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Merus First in Class (FIC) Antibody Drugs Product Portfolio
  138. 8.23.5 Merus Recent Developments
  139. 8.24 Lytgobi
  140. 8.24.1 Lytgobi Company Information
  141. 8.24.2 Lytgobi Business Overview
  142. 8.24.3 Lytgobi First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio
  144. 8.24.5 Lytgobi Recent Developments
  145. 8.25 Litfulo
  146. 8.25.1 Litfulo Company Information
  147. 8.25.2 Litfulo Business Overview
  148. 8.25.3 Litfulo First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Litfulo First in Class (FIC) Antibody Drugs Product Portfolio
  150. 8.25.5 Litfulo Recent Developments
  151. 8.26 Immatics
  152. 8.26.1 Immatics Company Information
  153. 8.26.2 Immatics Business Overview
  154. 8.26.3 Immatics First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Immatics First in Class (FIC) Antibody Drugs Product Portfolio
  156. 8.26.5 Immatics Recent Developments
  157. 8.27 Fabhalta
  158. 8.27.1 Fabhalta Company Information
  159. 8.27.2 Fabhalta Business Overview
  160. 8.27.3 Fabhalta First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio
  162. 8.27.5 Fabhalta Recent Developments
  163. 8.28 Bicara Therapeutics
  164. 8.28.1 Bicara Therapeutics Company Information
  165. 8.28.2 Bicara Therapeutics Business Overview
  166. 8.28.3 Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio
  168. 8.28.5 Bicara Therapeutics Recent Developments
  169. 8.29 Bayer Corporation
  170. 8.29.1 Bayer Corporation Company Information
  171. 8.29.2 Bayer Corporation Business Overview
  172. 8.29.3 Bayer Corporation First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  173. 8.29.4 Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio
  174. 8.29.5 Bayer Corporation Recent Developments
  175. 8.30 Arvinas
  176. 8.30.1 Arvinas Company Information
  177. 8.30.2 Arvinas Business Overview
  178. 8.30.3 Arvinas First in Class (FIC) Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  179. 8.30.4 Arvinas First in Class (FIC) Antibody Drugs Product Portfolio
  180. 8.30.5 Arvinas Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 First in Class (FIC) Antibody Drugs Value Chain Analysis
  2. 9.1.1 First in Class (FIC) Antibody Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 First in Class (FIC) Antibody Drugs Sales Mode & Process
  6. 9.2 First in Class (FIC) Antibody Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 First in Class (FIC) Antibody Drugs Distributors
  9. 9.2.3 First in Class (FIC) Antibody Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst